EUCTR2004-003989-15-IT进行中（未招募）不适用
Pegylated Liposomal Doxorubicin (Caleyx) in combination with Herceptin and Taxotere as first-line chemotherapy in metastatic breast cancer patients: A 2 stage Phase II, open label, Multicenter study.
SCHERING-PLOUGH0 个研究点开始时间: 2008年11月17日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
PEGYLATED LIPOSOMAL DOXORUBICIN (CAELYX), CISPLATINUMAND FLUOROURACIL AS CONTINUOUS INFUSION (CCF) PLUSTRASTUZUMAB (HERCEPTIN) IN THE PREOPERATIVE TREATMENT OFLOCALLY ADVANCED BREAST CANCER - NDlocally advanced breast cancerMedDRA version: 6.1Level: PTClassification code 10057654EUCTR2006-006010-15-ITISTITUTO EUROPEO DI ONCOLOGIA
进行中（未招募）
不适用
PEGYLATED LIPOSOMAL DOXORUBICIN (CAELYX), CISPLATINUM AND FLUOROURACIL AS CONTINUOUS INFUSION (CCF) IN LOCALLYADVANCED BREAST CANCER - NDlocally advanced breast cancerMedDRA version: 9.1Level: LLTClassification code 10057654Term: Breast cancer femaleEUCTR2006-004856-19-ITISTITUTO EUROPEO DI ONCOLOGIA
已完成
2 期
Treatment of Disseminated High Grade LymphomaLymphomaNCT00536393French Innovative Leukemia Organisation100
进行中（未招募）
1 期
RECHALLENGE WITH PEGYLATED LIPOSOMAL DOXORUBICIN ADDED TO TRABECTEDIN IN RECURRENT OVARIAN CANCER: A MULTICENTER, PROSPECTIVE TRIAL (REPRAB study – MITO 36)MedDRA version: 22.0Level: LLTClassification code 10026311Term: Malignant neoplasm of ovary and other uterine adnexaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10061535Term: Ovarian neoplasmSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10061344Term: Peritoneal neoplasmSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Ovarian cancerEUCTR2017-004690-14-ITFONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE64
已完成
不适用
Phase I Trail of pegylated liposomal doxorubicin (PLD) in combination with Irinotecan (CPT-11) in Patients with Platinum Refractory and Resistant Ovarian cancerPatients with platinum-refractory and resistant ovarian cancerJPRN-UMIN000005525Fukuoka University, School of Medicine6